

Author Index Volume 54 (2016)

The issue number is given in front of the pagination

- Aarsland, D., see Bonanni, L. (4) 1649–1657
Aarsland, D., see van Steenoven, I. (1) 287–295
Abadie, C., see Gourmaud, S. (4) 1659–1670
Abbate, C., see Arosio, B. (2) 417–425
Abrahams, J.P., see Tiiman, A. (3) 971–982
Acharya, N.K., see Goldwaser, E.L. (2) 445–456
Acuña-Ayala, H., see Calderón-Garcidueñas, L. (2) 597–613
Adam, K., see Tsolaki, M. (1) 129–133
Adeli, A., see Scharre, D.W. (3) 995–1004
Adzhubei, A.A., see Morozov, A.V. (2) 763–776
Agrawal, P., see Scharre, D.W. (3) 995–1004
Aiyaz, M., see Hakobyan, S. (2) 707–716
Aldebert, J., see Chapleau, M. (3) 941–955
Allali, G., V. Garibotto and F. Assal, Parkinsonism Differentiates Idiopathic Normal Pressure Hydrocephalus from Its Mimics (1) 123–127
Allen, H.R., see Myers, C.A. (4) 1359–1364
Allison, W.T., see Leighton, P.L.A. (1) 3–29
Almeida, O.F.X., see Li, Y. (1) 135–148
Alva, N., see Ettcheto, M. (1) 233–251
Alvarez, A.R., see Estrada, L.D. (3) 1193–1205
Amadio, M., see Marchesi, N. (2) 535–547
Amaratunga, D., see Wijesinghe, P. (4) 1607–1618
Amaro Jr, E., see Grinberg, L.T. (1) 169–174
Ambrose, C.T., The Role of Capillaries in the Lesser Ailments of Old Age and in Alzheimer's Disease and Vascular Dementia: The Potential of Pro-Therapeutic Angiogenesis (1) 31–43
Ames, D., see Connors, M.H. (1) 149–155
Amin, N.D., see Binukumar, B.K. (2) 525–533
Andersen, B.G., see Zakarias, J.K. (3) 1183–1192
Andersohn, F., see Brüuggenjürgen, B. (4) 1365–1372
Anderson, W.S., see Lozano, A.M. (2) 777–787
Andrés-Benito, P., see Aso, E. (3) 903–912
Anghinah, R., see Grinberg, L.T. (1) 169–174
Antoine, P., see El Haj, M. (2) 515–523
Anton, M., see Ordoñez-Gutierrez, L. (2) 645–656
Antuono, P.G., see Chen, G. (3) 983–993
Apostolova, I., see Ritter, K. (4) 1319–1331
Arcaro, M., see Cioffi, S.M.G. (2) 717–721
Arnold, S.E., see Roalf, D.R. (1) 325–335
Arora, A.S., see Karch, A. (4) 1385–1393
Arosio, B., M. Casati, C. Gussago, E. Ferri, C. Abbate, V. Scortichini, E. Colombo, P.D. Rossi and D. Mari, Adenosine Type A_{2A} Receptor in Peripheral Cell from Patients with Alzheimer's Disease, Vascular Dementia, and Idiopathic Normal Pressure Hydrocephalus: A New/Old Potential Target (2) 417–425
Asaad, W.F., see Lozano, A.M. (2) 777–787
Ashford, J.W., see Durazzo, T.C. (1) 99–107
Aso, E., P. Andrés-Benito and I. Ferrer, Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model (3) 903–912
Aso, E., see López-González, I. (2) 471–475
Assal, F., see Allali, G. (1) 123–127
Astakhova, T.M., see Morozov, A.V. (2) 763–776
Asthana, S., see Racine, A.M. (4) 1395–1408
Auckland, L.D., see Parham, C.L. (4) 1629–1647
Audekerke, J.V., see Blockx, I. (2) 723–735
Auladell, C., see Ettcheto, M. (1) 233–251
Avila-Ramírez, J., see Calderón-Garcidueñas, L. (2) 597–613
Azqueta, A., see Bengoetxea, X. (3) 1085–1094
Baéz, S., see Santamaría-García, H. (3) 957–970
Baird, A., see Hakobyan, S. (2) 707–716
Baker, S., J.C. Polanco and J. Götz, Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice (3) 1207–1217
Baltuch, G., see Lozano, A.M. (2) 777–787
Bannach, O., see Hülsemann, M. (1) 79–88
Bar, R., see Boehm-Cagan, A. (3) 1219–1233
Barcikowska, M., see Mandecka, M. (1) 157–168
Barczak, A., see Mandecka, M. (1) 157–168
Bard, F., see Blockx, I. (2) 723–735
Barnes, A., see Westona, P.S.J. (4) 1297–1302
Barocco, F., see Cioffi, S.M.G. (2) 717–721

- Barrentine, L.W., see Shankle, W.R. (3) 1073–1084
- Bartorelli, L., see Sepe-Monti, M. (3) 1235–1246
- Baschieri, F., see Chiasserini, D. (1) 55–67
- Bauer, C., see Klafki, H.-W. (2) 691–705
- Beas-Zarate, C., see Ettcheto, M. (1) 233–251
- Beckelman, B.C., S. Day, X. Zhou, M. Donohue, G.K. Gouras, E. Klann, C.D. Keene and T. Ma, Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer's Disease (2) 669–678
- Bell, J.S., see Tan, E.C.K. (4) 1425–1435
- Bengoetxea, X., A. López de Cerain, A. Azqueta and M.J. Ramirez, Purported Interactions of Amyloid- β and Glucocorticoids in Cytotoxicity and Genotoxicity: Implications in Alzheimer's Disease (3) 1085–1094
- Benito-Cuesta, I., see Ordoñez-Gutierrez, L. (2) 645–656
- Bergquist, J., see Musunuri, S. (4) 1671–1686
- Berman, S.E., see Racine, A.M. (4) 1395–1408
- Bernasconi, M.P., see Mazzeo, S. (4) 1495–1508
- Berti, A., see Luccarini, I. (2) 737–750
- Bertoux, M., S. Ramanan, A. Slachevsky, S. Wong, F. Henriquez, G. Musa, C. Delgado, E. Flanagan, M. Bottlaender, M. Sarazin, M. Hornberger and B. Dubois, So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia (3) 1005–1014
- Bhaskar, M., see Binukumar, B.K. (2) 525–533
- Bickel, H., see Hesper, K. (1) 185–199
- Bickel, H., see Wolfsgruber, S. (3) 1135–1146
- Bielicki, J.K., see Boehm-Cagan, A. (3) 1219–1233
- Bigio, E.H., see Guo, L. (3) 1157–1167
- Bilgel, M., see Racine, A.M. (4) 1395–1408
- Binukumar, B.K., S.L. Pelech, C. Sutter, V. Shukla, N.D. Amin, P. Grant, M. Bhaskar, S. Skuntz, J. Steiner and H.C. Pant, Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDK1 Against 70 Protein Kinases (2) 525–533
- Biscetti, L., see Chiasserini, D. (1) 55–67
- Bittner, D., see Ritter, K. (4) 1319–1331
- Bix, G., see Parham, C.L. (4) 1629–1647
- Bjerke, M., see Somers, C. (1) 383–395
- Blanc, F., see van Steenoven, I. (1) 287–295
- Blawath, S., see Middelstädt, J. (1) 253–268
- Bleckwenn, M., see Hesper, K. (1) 185–199
- Blennow, K., see Portelius, E. (4) 1593–1605
- Blennow, K., see Racine, A.M. (4) 1395–1408
- Blockx, I., S. Einstein, P.-J. Guns, J.V. Audekerke, C. Guglielmetti, W. Zago, D. Roose, M. Verhoye, A. Van der Linden and F. Bard, Monitoring Blood-Brain Barrier Integrity Following Amyloid- β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model (2) 723–735
- Bodin, M., see Portelius, E. (4) 1593–1605
- Boehm-Cagan, A., R. Bar, O. Liraz, J.K. Bielicki, J.O. Johansson and D.M. Michaelson, ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies (3) 1219–1233
- Bogucka-Kocka, A., see Ułamek-Kozioł, M. (1) 113–121
- Bogucki, J., see Ułamek-Kozioł, M. (1) 113–121
- Bomanji, J.B., see Westona, P.S.J. (4) 1297–1302
- Bonanni, L., R. Franciotti, F. Nobili, M.G. Kramberger, J.-P. Taylor, S. Garcia-Ptacek, N.W. Falasca, F. Famà, R. Cromarty, M. Onofrj, D. Aarsland and on behalf of the E-DLB study group, EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study (4) 1649–1657
- Bonanni, L., see van Steenoven, I. (1) 287–295
- Booth, K., see Brody, M. (4) 1509–1519
- Bossert, I., see Chincarini, A. (4) 1437–1457
- Bottlaender, M., see Bertoux, M. (3) 1005–1014
- Boundy, K., see Connors, M.H. (1) 149–155
- Bourgade, K., G. Dupuis, E.H. Frost and T. Fülöp Jr., Anti-Viral Properties of Amyloid- β Peptides (3) 859–878
- Boutoleau-Bretonnière, C., see Magnin, E. (4) 1459–1471
- Brambati, S.M., see Chapleau, M. (3) 941–955
- Brashear, H.R., see Brody, M. (4) 1509–1519
- Brenner, W., see Ritter, K. (4) 1319–1331
- Brettschneider, C., see Hesper, K. (1) 185–199
- Brettschneider, C., see Wolfsgruber, S. (3) 1135–1146
- Brezovakova, V., see Zimova, I. (2) 831–843
- Britton, G.B., see Villarreal, A.E. (3) 897–901
- Brodsky, H., see Connors, M.H. (1) 149–155
- Brodthmann, A., see Malpas, C.B. (1) 223–232
- Brody, M., E. Liu, J. Di, M. Lu, R.A. Margolin, J.L. Werth, K. Booth, A. Shadman, H.R. Brashear and G. Novak, A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease (4) 1509–1519
- Broich, K., see Gomm, W. (2) 801–808
- Bronskill, S.E., see Jaakkimainen, R.L. (1) 337–349
- Brouillette, R.M., see Myers, C.A. (4) 1359–1364
- Brown, E.E., Y. Iwata, J.K. Chung, P. Gerretsen and A. Graff-Guerrero, Tau in Late-Life Depres-

- sion: A Systematic Review and Meta-Analysis (2) 615–633
- Brüuggenjürgen, B., F. Andersohn, J. Burkowitz, N. Ezzat, M. Gaudig and S.N. Willich, Cohort Study on Predictors of Need for Nursing Care in Alzheimer's Disease: An Analysis of Health-care Data (4) 1365–1372
- Brzozowska, J., see Ułamek-Kozioł, M. (1) 113–121
- Buchert, R., see Ritter, K. (4) 1319–1331
- Budziszewska, M., see Mandecka, M. (1) 157–168
- Buhl, P., see Struhal, W. (2) 657–667
- Burke, A., see Lozano, A.M. (2) 777–787
- Burkowitz, J., see Brüuggenjürgen, B. (4) 1365–1372
- Burnysheva, K.M., see Morozov, A.V. (2) 763–776
- Butt, D., see Jaakkimainen, R.L. (1) 337–349
- Caffarra, P., see Cioffi, S.M.G. (2) 717–721
- Cai, R., see Sun, J. (1) 175–184
- Calabresi, P., see Chiasserini, D. (1) 55–67
- Calderón-Garcidueñas, A., see Calderón-Garcidueñas, L. (2) 597–613
- Calderón-Garcidueñas, L., J. Avila-Ramírez, A. Calderón-Garcidueñas, T. González-Heredia, H. Acuña-Ayala, C.-k. Chao, C. Thompson, R. Ruiz-Ramos, V. Cortés-González, L. Martínez-Martínez, M.A. García-Pérez, J. Reis, P.S. Mukherjee, R. Torres-Jardón and I. Lachmann, Cerebrospinal Fluid Biomarkers in Highly Exposed PM_{2.5} Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents (2) 597–613
- Calderón-Garcidueñas, L., Smoking and Cerebral Oxidative Stress and Air Pollution: A Dreadful Equation with Particulate Matter Involved and One More Powerful Reason Not to Smoke Anything! (1) 109–112
- Callahan, J., see Malpas, C.B. (1) 223–232
- Callas, P.W., see Cushman, M. (2) 497–503
- Calvo-Perxas, L., see Turró-Garriga, O. (4) 1551–1560
- Calvo-Rodríguez, M., M. García-Durillo, C. Villalobos and L. Núñez, Aging Enables Ca²⁺ Overload and Apoptosis Induced by Amyloid- β Oligomers in Rat Hippocampal Neurons: Neuroprotection by Non-Steroidal Anti-Inflammatory Drugs and R-Flurbiprofen in Aging Neurons (1) 207–221
- Cam, M., see Portelius, E. (4) 1593–1605
- Camins, A., see Ettcheto, M. (1) 233–251
- Canudas, J., see Pérez-Grijalba, V. (2) 751–762
- Carbonell, T., see Ettcheto, M. (1) 233–251
- Carlsson, C.M., see Racine, A.M. (4) 1395–1408
- Carmona, M., see López-González, I. (2) 471–475
- Casabona, D., see Pérez-Grijalba, V. (2) 751–762
- Casamenti, F., see Luccarini, I. (2) 737–750
- Casati, M., see Arosio, B. (2) 417–425
- Cavone, L., see Luccarini, I. (2) 737–750
- Cecchetti, G., see Mazzeo, S. (4) 1495–1508
- Chakravarty, M.M., see Lozano, A.M. (2) 777–787
- Chamorro, D., see Estrada, L.D. (3) 1193–1205
- Chang, L., see Li, Y. (1) 135–148
- Chang, S.-I., see Scharre, D.W. (3) 995–1004
- Chang, Y.-T., see Portelius, E. (4) 1593–1605
- Chao, C.-k., see Calderón-Garcidueñas, L. (2) 597–613
- Chapleau, M., J. Aldebert, M. Montembeault and S.M. Brambati, Atrophy in Alzheimer's Disease and Semantic Dementia: An ALE Meta-Analysis of Voxel-Based Morphometry Studies (3) 941–955
- Chapman, B.P., see Ren, P. (1) 69–78
- Chatterjee, P., see Rai, N. (3) 1147–1155
- Chen, C.L.-H., see Liu, S. (2) 585–595
- Chen, G., H. Shu, G. Chen, B.D. Ward, P.G. Antuono, Z. Zhang, S.-J. Li and Alzheimer's Disease Neuroimaging Initiative, Staging Alzheimer's Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers (3) 983–993
- Chen, G., see Chen, G. (3) 983–993
- Chen, J.X., see Yu, Q. (2) 679–690
- Chen, K., see Wang, P. (1) 359–371
- Chen, X., see Zhang, H. (3) 1095–1112
- Chen, Y., see Yu, L. (1) 297–306
- Cheng, B., see Li, D. (1) 89–98
- Cheung, C.Y., see Liu, S. (2) 585–595
- Chiasserini, D., L. Biscetti, L. Farotti, P. Eusebi, N. Salvadori, V. Lisetti, F. Baschieri, E. Chipi, G. Frattini, E. Stoops, H. Vanderstichele, P. Calabresi and L. Parnetti, Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine (1) 55–67
- Chincarini, A., F. Sensi, L. Rei, I. Bossert, S. Morbelli, U.P. Guerra, G. Frisoni, A. Padovani, F. Nobili and for the Alzheimer's Disease Neuroimaging Initiative, Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis (4) 1437–1457
- Chipi, E., see Chiasserini, D. (1) 55–67
- Cho, H., see Noh, Y. (3) 1015–1026
- Cho, S.-J., see Kang, J.M. (3) 879–889
- Chodakowska-Żebrowska, M., see Mandecka, M. (1) 157–168

- Choe, Y.S., see Noh, Y. (3) 1015–1026
- Choo, I.H., see Seo, E.H. (2) 559–568
- Choo, I.H., see Seo, E.H. (3) 933–940
- Chou, M.-C., see Ho, B.-L. (1) 351–357
- Christian, B.T., see Racine, A.M. (4) 1395–1408
- Chu, W.C.W., see Lou, W. (1) 397–409
- Chung, J.K., see Brown, E.E. (2) 615–633
- Cioffi, S.M.G., D. Galimberti, F. Barocco, M. Spallazzi, C. Fenoglio, M. Serpente, M. Arcaro, S. Gardini, E. Scarpini and P. Caffarra, Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation (2) 717–721
- Clark, L.R., see Mueller, K.D. (4) 1539–1550
- Clark, L.R., see Racine, A.M. (4) 1395–1408
- Clarnette, R., see Connors, M.H. (1) 149–155
- Collins, S., see Malpas, C.B. (1) 223–232
- Colombo, E., see Arosio, B. (2) 417–425
- Colombrita, C., see Marchesi, N. (2) 535–547
- Comi, G., see Mazzeo, S. (4) 1495–1508
- Conde-Sala, J.-L., see Turró-Garriga, O. (4) 1551–1560
- Connors, M.H., D. Ames, K. Boundy, R. Clarnette, S. Kurrle, A. Mander, J. Ward, M. Woodward and H. Brodaty, Mortality in Mild Cognitive Impairment: A Longitudinal Study in Memory Clinics (1) 149–155
- Corcoran, N.M., see Malpas, C.B. (1) 223–232
- Correani, V., see Martire, S. (1) 307–324
- Cortés-González, V., see Calderón-Garcidueñas, L. (2) 597–613
- Covaci, A., see Portelius, E. (4) 1593–1605
- Cras, P., see Somers, C. (1) 383–395
- Crocco, E., see Curiel, R.E. (2) 793–799
- Cromarty, R., see Bonanni, L. (4) 1649–1657
- Cubinkova, V., see Zimova, I. (2) 831–843
- Curiel, R.E., E. Crocco, M. Rosado, R. Duara, M.T. Greig, A. Raffo and D.A. Loewenstein, A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults (2) 793–799
- Curole, M.V., see Shankle, W.R. (3) 1073–1084
- Cushman, M., P.W. Callas, L.A. McClure, F.W. Unverzagt, V.J. Howard, S.R. Gillett, E.L. Thacker and V.G. Wadley, N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the REGARDS Cohort (2) 497–503
- Czuczwar, S.J., see Ułamek-Kozioł, M. (1) 113–121
- D’Antonio, F., see Trebbastoni, A. (3) 1039–1045
- d’Erme, M., see Martire, S. (1) 307–324
- da Graça M. Martin, M., see Grinberg, L.T. (1) 169–174
- Das, S., see Gertje, E.C. (3) 1027–1037
- Davies, P., see Mead, E. (4) 1521–1538
- Davis, A.B., see Myers, C.A. (4) 1359–1364
- Day, S., see Beckelman, B.C. (2) 669–678
- De Beaumont, L., S. Pelleieux, L. Lamarre-Théroux, D. Dea, J. Poirier and the Alzheimer’s Disease Cooperative Study, Butyrylcholinesterase K and Apolipoprotein E-ε4 Reduce the Age of Onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects (3) 913–922
- De Deyn, P., see Portelius, E. (4) 1593–1605
- De Deyn, P.-P., see Somers, C. (1) 383–395
- de la Sayette, V., see Magnin, E. (4) 1459–1471
- de Lena, C., see Trebbastoni, A. (3) 1039–1045
- De Roeck, E., see Somers, C. (1) 383–395
- De Roeck, N., see Somers, C. (1) 383–395
- De Silva, K.R.D., see Wijesinghe, P. (4) 1607–1618
- De Vil, B., see Somers, C. (1) 383–395
- Dea, D., see De Beaumont, L. (3) 913–922
- Death Preparation and Boredom Reduction as Functions of Reminiscence in Alzheimer’s Disease (2) 515–523
- Delgado, C., see Bertoux, M. (3) 1005–1014
- Demattei, C., see Renard, D. (4) 1291–1295
- Démonet, J.-F., see Magnin, E. (4) 1459–1471
- Desai, G.R., see Rai, N. (3) 1147–1155
- Desmond, P., see Malpas, C.B. (1) 223–232
- Dey, A.B., see Rai, N. (3) 1147–1155
- Dey, S., see Rai, N. (3) 1147–1155
- Di, J., see Brody, M. (4) 1509–1519
- Di Lazzaro, V., see Tombini, M. (4) 1619–1627
- Dickensheets, T., see Johnson, L.A. (1) 201–206
- Dickeson, S.K., see Parham, C.L. (4) 1629–1647
- Dickson, J., see Westona, P.S.J. (4) 1297–1302
- Doblhammer, G., see Gomm, W. (2) 801–808
- Dobson, R., see Hakobyan, S. (2) 707–716
- Doi, T., see Makizako, H. (4) 1473–1482
- Donohue, M., see Beckelman, B.C. (2) 669–678
- Dovas, K., see Tsolaki, M. (1) 129–133
- Dovidchenko, N.V., see Selivanova, O.M. (2) 821–830
- Drake, K.E., see Lozano, A.M. (2) 777–787
- Duara, R., see Curiel, R.E. (2) 793–799
- Dubner, L., see Varghese, M. (2) 477–496
- Dubois, B., see Bertoux, M. (3) 1005–1014
- Dulcey, A.E., see Estrada, L.D. (3) 1193–1205
- Dumurgier, J., see Magnin, E. (4) 1459–1471
- Dupuis, G., see Bourgade, K. (3) 859–878
- Durazzo, T.C., M. Korecka, J.Q. Trojanowski, M.W. Weiner, R. O’ Hara, J.W. Ashford, L.M. Shaw

- and for the Alzheimer's Disease Neuroimaging Initiative, Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers (1) 99–107
- Durieu, E., see Portelius, E. (4) 1593–1605
- Duron, E., see Magnin, E. (4) 1459–1471
- Dwivedi, S., see Rai, N. (3) 1147–1155
- Dzhus, U.F., see Selivanova, O.M. (2) 821–830
- Edwards, M., see Johnson, L.A. (1) 201–206
- Edwards, M., see Villarreal, A.E. (3) 897–901
- Einstein, S., see Blockx, I. (2) 723–735
- El Haj, M. and P. Antoine
- El Khoury, J., see Guo, L. (3) 1157–1167
- Enderle, A., see Magnin, E. (4) 1459–1471
- Engelborghs, S., see Somers, C. (1) 383–395
- Erlandsson, A., see Musunuri, S. (4) 1671–1686
- Ernst, A., see Wolfsgruber, S. (3) 1135–1146
- Erokhov, P.A., see Morozov, A.V. (2) 763–776
- Eslambolchilar, P., see Jenkins, A. (3) 1169–1182
- Estrada, L.D., D. Chamorro, M.J. Yañez, M. Gonzalez, N. Leal, R. von Bernhardt, A.E. Dulcey, J. Marugan, M. Ferrer, C. Soto, S. Zanlungo, N.C. Inestrosa and A.R. Alvarez, Reduction of Blood Amyloid- β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition (3) 1193–1205
- Estrella, M., see Ritter, K. (4) 1319–1331
- Ettchet, M., D. Petrov, I. Pedrós, N. Alva, T. Carbonell, C. Beas-Zarate, M. Pallas, C. Auladell, J. Folch and A. Camins, Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice (1) 233–251
- Eusebi, P., see Chiasserini, D. (1) 55–67
- Evain, S., see Magnin, E. (4) 1459–1471
- Eversden, S., see Mead, E. (4) 1521–1538
- Evgen'ev, M.B., see Morozov, A.V. (2) 763–776
- Exley, C., see Mirzaa, A. (4) 1333–1338
- Ezzat, N., see Brüuggenjürgen, B. (4) 1365–1372
- Falasca, N.W., see Bonanni, L. (4) 1649–1657
- Falautano, M., see Mazzeo, S. (4) 1495–1508
- Famà, F., see Bonanni, L. (4) 1649–1657
- Fandos, N., see Pérez-Grijalba, V. (2) 751–762
- Fang, D., see Yu, Q. (2) 679–690
- Fang, Y., see Li, Y. (1) 135–148
- Farotti, L., see Chiasserini, D. (1) 55–67
- Farr, S.A., K.E. Sandoval, M.L. Niehoff, K.A. Witt, V.B. Kumar and J.E. Morley, Peripheral Administration of GSK-3 β Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer's Disease (4) 1339–1348
- Fenoglio, C., see Cioffi, S.M.G. (2) 717–721
- Fernandez, L., see López-González, I. (2) 471–475
- Fernandez-Perez, I., see Ordoñez-Gutierrez, L. (2) 645–656
- Ferrer, I., see Aso, E. (3) 903–912
- Ferrer, I., see López-González, I. (2) 471–475
- Ferrer, M., see Estrada, L.D. (3) 1193–1205
- Ferri, E., see Arosio, B. (2) 417–425
- Fiebach, J.B., see Ritter, K. (4) 1319–1331
- Filho, W.J., see Grinberg, L.T. (1) 169–174
- Filipcik, P., see Zimova, I. (2) 831–843
- Filipek-Gliszczyńska, A., see Mandecka, M. (1) 157–168
- Fink, A., see Gomm, W. (2) 801–808
- Fiorino, A., see Mazzeo, S. (4) 1495–1508
- Fladby, T., see van Steenoven, I. (1) 287–295
- Flajolet, M., see Portelius, E. (4) 1593–1605
- Flanagan, E., see Bertoux, M. (3) 1005–1014
- Foil, H., see Myers, C.A. (4) 1359–1364
- Folch, J., see Ettchet, M. (1) 233–251
- Folkerts, A.-K., see Middelstädt, J. (1) 253–268
- Fontaine, G., see Portelius, E. (4) 1593–1605
- Fontana, M., see Martire, S. (1) 307–324
- Foot, K.D., see Lozano, A.M. (2) 777–787
- Forte, E., see Martire, S. (1) 307–324
- Fosdick, L., see Lozano, A.M. (2) 777–787
- Fox, N.C., see Westona, P.S.J. (4) 1297–1302
- Foxe, D., see Midorikawa, A. (2) 549–558
- Franciotti, R., see Bonanni, L. (4) 1649–1657
- Frattini, G., see Chiasserini, D. (1) 55–67
- Fried, I., Brain Stimulation in Alzheimer's Disease (2) 789–791
- Frisoni, G., see Chincarini, A. (4) 1437–1457
- Fritz, N., see Scharre, D.W. (3) 995–1004
- Frost, E.H., see Bourgade, K. (3) 859–878
- Fu, Y.H., J.-H.T. Hsiao, G. Paxinos, G.M. Halliday and W.S. Kim, ABCA7 Mediates Phagocytic Clearance of Amyloid- β in the Brain (2) 569–584
- Fuchs, A., see Hesser, K. (1) 185–199
- Fuchs, A., see Wolfsgruber, S. (3) 1135–1146
- Fülöp Jr., T., see Bourgade, K. (3) 859–878
- Funahashi, Y., see Yoshino, Y. (4) 1349–1357
- Furmaga-Jabłońska, W., see Ułamek-Koziół, M. (1) 113–121
- Fuso, A., see Martire, S. (1) 307–324
- Gabelle, A., see Magnin, E. (4) 1459–1471
- Gabelle, A., see Renard, D. (4) 1291–1295
- Gable, S., see Levy, B. (4) 1259–1272

- Gabryelewicz, T., see Mandacka, M. (1) 157–168
- Gago, M., see Lima, S. (3) 1113–1121
- Galimberti, D., see Cioffi, S.M.G. (2) 717–721
- Galons, H., see Portelius, E. (4) 1593–1605
- Galzitskaya, O.V., see Selivanova, O.M. (2) 821–830
- Gamboa, A., see Johnson, L.A. (1) 201–206
- Gao, X., see Li, Y. (1) 135–148
- Garbis, S.D., see Portelius, E. (4) 1593–1605
- García, A., see Santamaría-García, H. (3) 957–970
- García-Durillo, M., see Calvo-Rodríguez, M. (1) 207–221
- García-Pérez, M.A., see Calderón-Garcidueñas, L. (2) 597–613
- García-Ptacek, S., see Bonanni, L. (4) 1649–1657
- Gardini, S., see Cioffi, S.M.G. (2) 717–721
- Garibotto, V., see Allali, G. (1) 123–127
- Garre-Olmo, J., see Turró-Garriga, O. (4) 1551–1560
- Garrett, C., see Lima, S. (3) 1113–1121
- Gascón-Bayarri, J., see Turró-Garriga, O. (4) 1551–1560
- Gasse, C., see Stevnsborg, L. (2) 505–514
- Gasse, C., see Zakarias, J.K. (3) 1183–1192
- Gaudig, M., see Brüuggenjürgen, B. (4) 1365–1372
- Genc, S., see Malpas, C.B. (1) 223–232
- Georgiadis, K., see Tsolaki, M. (1) 129–133
- Gerretsen, P., see Brown, E.E. (2) 615–633
- Gertje, E.C., J. Pluta, S. Das, L. Mancuso, D. Kliot, P. Yushkevich and D. Wolk, Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer's Disease (3) 1027–1037
- Geula, C., see Guo, L. (3) 1157–1167
- Giacobbe, P., see Lozano, A.M. (2) 777–787
- Giannakopoulos, P., see Zhang, H. (3) 1095–1112
- Gibson, Y., see Mead, E. (4) 1521–1538
- Gil-Kulik, P., see Ułamek-Kozioł, M. (1) 113–121
- Gill, D.P., see Heath, M. (3) 923–931
- Gillett, S.R., see Cushman, M. (2) 497–503
- Giubilei, F., see Sepe-Monti, M. (3) 1235–1246
- Glyakina, A.V., see Selivanova, O.M. (2) 821–830
- Godsey, G., see Goldwaser, E.L. (2) 445–456
- Goldwaser, E.L., N.K. Acharya, A. Sarkar, G. Godsey and R.G. Nagele, Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease (2) 445–456
- Gomm, W., K. von Holt, F. Thomé, K. Broich, W. Maier, K. Weckbecker, A. Fink, G. Doblhammer and B. Haenisch, Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data (2) 801–808
- Gonzalez, M., see Estrada, L.D. (3) 1193–1205
- González-Heredia, T., see Calderón-Garcidueñas, L. (2) 597–613
- Goodson, R., see Mead, E. (4) 1521–1538
- Goossens, J., see Somers, C. (1) 383–395
- Gorrie, C., see Wijesinghe, P. (4) 1607–1618
- Götz, J., see Baker, S. (3) 1207–1217
- Gouras, G.K., see Beckelman, B.C. (2) 669–678
- Gourmaud, S., F. Mouton-Liger, C. Abadie, E.F. Meurs, C. Paquet and J. Hugon, Dual Kinase Inhibition Affords Extended *in vitro* Neuroprotection in Amyloid- β Toxicity (4) 1659–1670
- Gövercin, M., see Ritter, K. (4) 1319–1331
- Govoni, S., see Marchesi, N. (2) 535–547
- Graff-Guerrero, A., see Brown, E.E. (2) 615–633
- Grajales, S., see Villarreal, A.E. (3) 897–901
- Grant, P., see Binukumar, B.K. (2) 525–533
- Gräslund, A., see Tiiman, A. (3) 971–982
- Green, D., see Jaakkimainen, R.L. (1) 337–349
- Greenway, F.L., see Myers, C.A. (4) 1359–1364
- Gregory, M.A., see Heath, M. (3) 923–931
- Greig, M.T., see Curiel, R.E. (2) 793–799
- Grigorashvili, E.I., see Selivanova, O.M. (2) 821–830
- Grinberg, L.T., R. Anghinah, C.F. Nascimento, E. Amaro Jr, R.P. Leite, M. da Graça M. Martin, M.S. Naslavsky, L.T. Takada, W.J. Filho, C.A. Pasqualucci and R. Nitrini, Chronic Traumatic Encephalopathy Presenting as Alzheimer's Disease in a Retired Soccer Player (1) 169–174
- Griswold-Prenner, I., see Parham, C.L. (4) 1629–1647
- Guerra, U.P., see Chincarini, A. (4) 1437–1457
- Guglielmetti, C., see Blockx, I. (2) 723–735
- Guns, P.-J., see Blockx, I. (2) 723–735
- Guo, L., A. Rezvani, L. Kukreja, R. Hoveyda, E.H. Bigio, M.-M. Mesulam, J. El Khoury and C. Geula, Postmortem Adult Human Microglia Proliferate in Culture to High Passage and Maintain Their Response to Amyloid- β (3) 1157–1167
- Guo, X., see Wang, P. (1) 359–371
- Gussago, C., see Arosio, B. (2) 417–425
- Haenisch, B., see Gomm, W. (2) 801–808
- Hafermann, H., see Klafki, H.-W. (2) 691–705
- Häggmark-Månberg, A., see Musunuri, S. (4) 1671–1686
- Hakobyan, S., K. Harding, M. Aiyaz, A. Hye, R. Dobson, A. Baird, B. Liu, C.L. Harris, S. Lovestone and B.P. Morgan, Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease (2) 707–716
- Hall, J., see Johnson, L.A. (1) 201–206

- Haller, S., see Zhang, H. (3) 1095–1112
- Halliday, G.M., see Fu, Y.H. (2) 569–584
- Hamilton, L., see Mead, E. (4) 1521–1538
- Hampel, H., see Ritter, K. (4) 1319–1331
- Hannequin, D., see Magnin, E. (4) 1459–1471
- Hara, H., F. Ono, S. Nakamura, S. Matsumoto, H. Jin, N. Hattori and T. Tabira, An Oral A β Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in A β Oligomers (3) 1047–1059
- Hara, J., see Shankle, W.R. (3) 1073–1084
- Harding, K., see Hakobyan, S. (2) 707–716
- Harris, C.L., see Hakobyan, S. (2) 707–716
- Hata, S., see Portelius, E. (4) 1593–1605
- Hattori, N., see Hara, H. (3) 1047–1059
- Hausmann, U., see Klafki, H.-W. (2) 691–705
- Haynes, J.-D., see Ritter, K. (4) 1319–1331
- Heath, M., J. Weiler, M.A. Gregory, D.P. Gill and R.J. Petrella, A Six-Month Cognitive-Motor and Aerobic Exercise Program Improves Executive Function in Persons with an Objective Cognitive Impairment: A Pilot Investigation Using the Antisaccade Task (3) 923–931
- Heikkilä, K., see Iso-Markku, P. (4) 1303–1317
- Hemachandra Reddy, P., see Vijayan, M. (2) 427–443
- Henriquez, F., see Bertoux, M. (3) 1005–1014
- Hermann, B., see Mueller, K.D. (4) 1539–1550
- Herrera, J.L., see Ordoñez-Gutierrez, L. (2) 645–656
- Herrmann, N., see Jaakkimainen, R.L. (1) 337–349
- Herrmann, N., see Rosenberg, P.B. (1) 373–381
- Herrmann, Y., see Hülsemann, M. (1) 79–88
- Heser, K., M. Bleckwenn, B. Wiese, S. Mamone, S.G. Riedel-Heller, J. Stein, D. Lühmann, T. Posselt, A. Fuchs, M. Pentzek, S. Weyerer, J. Werle, D. Weeg, H. Bickel, C. Brettschneider, H.-H. König, W. Maier, M. Scherer and M. Wagner for the AgeCoDe Study Group, Late-Life Depressive Symptoms and Lifetime History of Major Depression: Cognitive Deficits are Largely Due to Incipient Dementia rather than Depression (1) 185–199
- Hicks, R.J., see Malpas, C.B. (1) 223–232
- Hilal, S., see Liu, S. (2) 585–595
- Hirtz, C., see Renard, D. (4) 1291–1295
- Ho, B.-L., Y.-H. Kao, M.-C. Chou and Y.-H. Yang, Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease (1) 351–357
- Ho, L., see Varghese, M. (2) 477–496
- Hodges, J.R., see Midorikawa, A. (2) 549–558
- Honda, K., Cerebral Arterial Occlusion Did Not Promote the Prevalence of Cerebral Amyloid Angiopathy (1) 269–274
- Hong, X., see Wang, H. (1) 275–286
- Hong, Y., see Yu, L. (1) 297–306
- Hornberger, M., see Bertoux, M. (3) 1005–1014
- Hotta, R., see Makizako, H. (4) 1473–1482
- Hovens, C.M., see Malpas, C.B. (1) 223–232
- Hoveyda, R., see Guo, L. (3) 1157–1167
- Howard, V.J., see Cushman, M. (2) 497–503
- Hromadka, T., see Zimova, I. (2) 831–843
- Hsiao, J.-H.T., see Fu, Y.H. (2) 569–584
- Hu, B., see Wang, P. (1) 359–371
- Huang, P., see Qiu, T. (4) 1483–1493
- Huang, R., see Sun, J. (1) 175–184
- Huang, Y., see Li, D. (1) 89–98
- Huemer, M., see Struhal, W. (2) 657–667
- Hugon, J., see Gourmaud, S. (4) 1659–1670
- Hugon, J., see Magnin, E. (4) 1459–1471
- Hulathduwa, S., see Wijesinghe, P. (4) 1607–1618
- Hülsemann, M., C. Zafiu, K. Kühbach, N. Lühmann, Y. Herrmann, L. Peters, C. Linnartz, J. Willbold, K. Kravchenko, A. Kulawik, S. Willbold, O. Bannach and D. Willbold, Biofunctionalized Silica Nanoparticles: Standards in Amyloid- β Oligomer-Based Diagnosis of Alzheimer's Disease (1) 79–88
- Hutton, M., see Mead, E. (4) 1521–1538
- Hye, A., see Hakobyan, S. (2) 707–716
- Ibañez, A., see Santamaría-García, H. (3) 957–970
- Iga, J.-i., see Yoshino, Y. (4) 1349–1357
- Inestrosa, N.C., see Estrada, L.D. (3) 1193–1205
- Ingelsson, M., see Musunuri, S. (4) 1671–1686
- Inghilleri, M., see Trebbastoni, A. (3) 1039–1045
- Insardá, P., see Tombini, M. (4) 1619–1627
- Insua, D., see Pérez-Grijalba, V. (2) 751–762
- Iso-Markku, P., K. Waller, E. Vuoksimaa, K. Heikkilä, J. Rinne, J. Kaprio and U.M. Kujala, Midlife Physical Activity and Cognition Later in Life: A Prospective Twin Study (4) 1303–1317
- Itzhaki, R.F., Herpes and Alzheimer's Disease: Subversion in the Central Nervous System and How It Might Be Halted (4) 1273–1281
- Ivanov, A.S., see Khmeleva, S.A. (2) 809–819
- Ivers, N., see Jaakkimainen, R.L. (1) 337–349
- Iwata, N., see Matsunaga, S. (2) 635–643
- Iwata, Y., see Brown, E.E. (2) 615–633
- Jaakkimainen, R.L., S.E. Bronskill, M.C. Tierney, N. Herrmann, D. Green, J. Young, N. Ivers, D. Butt, J. Widdifield and K. Tu, Identification of

- Physician-Diagnosed Alzheimer's Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians' Electronic Medical Records (1) 337–349
- Jabłoński, M., see Ułamek-Kozioł, M. (1) 113–121
- Jadhav, S., see Zimova, I. (2) 831–843
- Jager, A., see Magnin, E. (4) 1459–1471
- Jakobsen, S., see Zakarias, J.K. (3) 1183–1192
- Januszewski, S., see Ułamek-Kozioł, M. (1) 113–121
- Jarvet, J., see Tiiman, A. (3) 971–982
- Jedynak, B., see Racine, A.M. (4) 1395–1408
- Jenkins, A., S. Lindsay, P. Eslambolchilar, I.M. Thornton and A. Tales, Administering Cognitive Tests Through Touch Screen Tablet Devices: Potential Issues (3) 1169–1182
- Jensen-Dahm, C., see Stevnsborg, L. (2) 505–514
- Jensen-Dahm, C., see Zakarias, J.K. (3) 1183–1192
- Jeon, S., see Noh, Y. (3) 1015–1026
- Jessen, F., see Wolfsgruber, S. (3) 1135–1146
- Jin, H., see Hara, H. (3) 1047–1059
- Johansson, J.O., see Boehm-Cagan, A. (3) 1219–1233
- John, B., see Trebbastoni, A. (3) 1039–1045
- Johnson, L.A., A. Gamboa, R. Vintimilla, M. Edwards, J. Hall, B. Weiser, M. Yadav, T. Dickensheets and S.E. O'Bryant, A Depressive Endophenotype for Predicting Cognitive Decline among Mexican American Adults and Elders (1) 201–206
- Johnson, S.C., see Mueller, K.D. (4) 1539–1550
- Johnson, S.C., see Racine, A.M. (4) 1395–1408
- Johnson, W.D., see Myers, C.A. (4) 1359–1364
- Jones, S., see Mead, E. (4) 1521–1538
- Kalbe, E., see Middelstädt, J. (1) 253–268
- Kang, J.M., B.K. Yeon, S.-J. Cho and Y.-H. Suh, Stem Cell Therapy for Alzheimer's Disease: A Review of Recent Clinical Trials (3) 879–889
- Kang, S.-H., see Seo, E.H. (2) 559–568
- Kao, Y.-H., see Ho, B.-L. (1) 351–357
- Kaprio, J., see Iso-Markku, P. (4) 1303–1317
- Karakostas, A., see Lazarou, I. (4) 1561–1591
- Karakostas, A., see Tsolaki, M. (1) 129–133
- Karathanasi, E., see Tsolaki, M. (1) 129–133
- Karch, A., F. Llorens, M. Schmitz, A.S. Arora, S. Zafar, P. Lange, C. Schmidt and I. Zerr, Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia (4) 1385–1393
- Karg, F., see Portelius, E. (4) 1593–1605
- Karlström, A.E., see Tiiman, A. (3) 971–982
- Karpov, V.L., see Morozov, A.V. (2) 763–776
- Kataki, M., see Scharre, D.W. (3) 995–1004
- Kayani, I., see Westona, P.S.J. (4) 1297–1302
- Keene, C.D., see Beckelman, B.C. (2) 669–678
- Kegelmeyer, D., see Scharre, D.W. (3) 995–1004
- Keller, J.N., see Myers, C.A. (4) 1359–1364
- Kestoras, D., see Mead, E. (4) 1521–1538
- Khaiboullina, S.F., see Mukhamedyarov, M.A. (4) 1373–1383
- Khmeleva, S.A., S.P. Radko, S.A. Kozin, Y.Y. Kiseleva, Y.V. Mezentsev, V.A. Mitkevich, L.K. Kurbatov, A.S. Ivanov and A.A. Makarov, Zinc-Mediated Binding of Nucleic Acids to Amyloid- β Aggregates: Role of Histidine Residues (2) 809–819
- Khoonsari, P.E., see Musunuri, S. (4) 1671–1686
- Kim, G.H., see Noh, Y. (3) 1015–1026
- Kim, H., see Seo, E.H. (3) 933–940
- Kim, H.J., see Noh, Y. (3) 1015–1026
- Kim, J.-H., see Noh, Y. (3) 1015–1026
- Kim, J.S., see Noh, Y. (3) 1015–1026
- Kim, M., see Zhang, H. (3) 1095–1112
- Kim, S.H., see Seo, E.H. (2) 559–568
- Kim, W.S., see Fu, Y.H. (2) 569–584
- Kindy, M.S., see Taheri, S. (3) 1061–1072
- King, A., see Mirzaa, A. (4) 1333–1338
- Kiseleva, Y.Y., see Khmeleva, S.A. (2) 809–819
- Kishi, T., see Matsunaga, S. (2) 635–643
- Kiyasov, A.P., see Mukhamedyarov, M.A. (4) 1373–1383
- Klafki, H.-W., H. Hafermann, C. Bauer, U. Haussmann, I. Kraus, J. Schuchhardt, S. Muck, N. Scherbaum and J. Wiltfang, Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid- β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort (2) 691–705
- Klann, E., see Beckelman, B.C. (2) 669–678
- Kleineidam, L., see Wolfsgruber, S. (3) 1135–1146
- Klimova, B., see Maresova, P. (3) 1123–1133
- Kliot, D., see Gertje, E.C. (3) 1027–1037
- Kloos, A., see Scharre, D.W. (3) 995–1004
- Koch, P., see Portelius, E. (4) 1593–1605
- Kocki, J., see Ułamek-Kozioł, M. (1) 113–121
- Kompatsiaris, I., see Lazarou, I. (4) 1561–1591
- Kompatsiaris, I., see Tsolaki, M. (1) 129–133
- König, H.-H., see Hesser, K. (1) 185–199
- König, H.-H., see Wolfsgruber, S. (3) 1135–1146
- Korecka, M., see Durazzo, T.C. (1) 99–107
- Koscik, R.L., see Mueller, K.D. (4) 1539–1550

- Koscik, R.L., see Racine, A.M. (4) 1395–1408
 Kostyk, S.K., see Scharre, D.W. (3) 995–1004
 Kozin, S.A., see Khmeleva, S.A. (2) 809–819
 Kramberger, M.G., see Bonanni, L. (4) 1649–1657
 Kramberger, M.G., see van Steenoven, I. (1) 287–295
 Kraus, I., see Klafki, H.-W. (2) 691–705
 Kravchenko, K., see Hülsemann, M. (1) 79–88
 Książak-Reding, H., see Varghese, M. (2) 477–496
 Kuca, K., see Maresova, P. (3) 1123–1133
 Kühbach, K., see Hülsemann, M. (1) 79–88
 Kujala, U.M., see Iso-Markku, P. (4) 1303–1317
 Kukreja, L., see Guo, L. (3) 1157–1167
 Kulawik, A., see Hülsemann, M. (1) 79–88
 Kulikova, A.A., see Morozov, A.V. (2) 763–776
 Kultima, K., see Musunuri, S. (4) 1671–1686
 Kumar, R., see Rai, N. (3) 1147–1155
 Kumar, V.B., see Farr, S.A. (4) 1339–1348
 Kumara, K.S., see Wijesinghe, P. (4) 1607–1618
 Kurbatov, L.K., see Khmeleva, S.A. (2) 809–819
 Kurrle, S., see Connors, M.H. (1) 149–155
 Kuruppu, S., N.W. Rajapakse, A.J. Spicer, H.C. Parkinson and A.I. Smith, Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels (3) 891–895
- Lachmann, I., see Calderón-Garcidueñas, L. (2) 597–613
 Lacosta, A.M., see Pérez-Grijalba, V. (2) 751–762
 Lahrman, H., see Struhel, W. (2) 657–667
 Lamarre-Théroux, L., see De Beaumont, L. (3) 913–922
 Lanctôt, K.L., see Rosenberg, P.B. (1) 373–381
 Landin-Romero, R., see Midorikawa, A. (2) 549–558
 Lange, C., see Ritter, K. (4) 1319–1331
 Lange, P., see Karch, A. (4) 1385–1393
 Lannfelt, L., see Musunuri, S. (4) 1671–1686
 Lapucci, A., see Lucarini, I. (2) 737–750
 LaRue, A., see Mueller, K.D. (4) 1539–1550
 Lazarou, I., A. Karakostas, T.G. Stavropoulos, T. Tsompanidis, G. Meditskos, I. Kompatsiaris and M. Tsolaki, A Novel and Intelligent Home Monitoring System for Care Support of Elders with Cognitive Impairment (4) 1561–1591
 Lazarou, I., see Tsolaki, M. (1) 129–133
 Leal, N., see Estrada, L.D. (3) 1193–1205
 Lee, J.-H., see Noh, Y. (3) 1015–1026
 Lee, J.M., see Noh, Y. (3) 1015–1026
 Lee, J.Y., see Portelius, E. (4) 1593–1605
 Lee, K.-H., see Noh, Y. (3) 1015–1026
 Lee, K.H., see Seo, E.H. (3) 933–940
 Lehmann, S., see Renard, D. (4) 1291–1295
 Leighton, P.L.A., and W.T. Allison, Protein Misfolding in Prion and Prion-Like Diseases: Reconsidering a Required Role for Protein Loss-of-Function (1) 3–29
 Leite, R.P., see Grinberg, L.T. (1) 169–174
 Lemstra, A.W., see van Steenoven, I. (1) 287–295
 Leoutsakos, J.-M., see Lozano, A.M. (2) 777–787
 Leuxe, C., see Portelius, E. (4) 1593–1605
 Levy, B., E. Tsoy and S. Gable, Developing Cognitive Markers of Alzheimer's Disease for Primary Care: Implications for Behavioral and Global Prevention (4) 1259–1272
 Leyton, C.E., see Midorikawa, A. (2) 549–558
 Li, D., Y. Huang, B. Cheng, J. Su, W.-X. Zhou and Y.-X. Zhang, Streptozotocin Induces Mild Cognitive Impairment at Appropriate Doses in Mice as Determined by Long-Term Potentiation and the Morris Water Maze (1) 89–98
 Li, G., see Zhang, H. (3) 1095–1112
 Li, H., see Li, Y. (1) 135–148
 Li, S., see Wang, H. (1) 275–286
 Li, S.-J., see Chen, G. (3) 983–993
 Li, Y., L. Chang, Y. Song, X. Gao, F. Roselli, J. Liu, W. Zhou, Y. Fang, W. Ling, H. Li, O.F.X. Almeida and Y. Wu, Astrocytic GluN2A and GluN2B Oppose the Synaptotoxic Effects of Amyloid- β_{1-40} in Hippocampal Cells (1) 135–148
 Liao, W., see Yuan, B. (4) 1409–1423
 Lima, L.M., see Mukhamedyarov, M.A. (4) 1373–1383
 Lima, S., M. Gago, C. Garrett and M.G. Pereira, Predictors and Moderators of Quality of Life in Alzheimer's Disease Patients (3) 1113–1121
 Lin, F., see Ren, P. (1) 69–78
 Linder, S., see Scharre, D.W. (3) 995–1004
 Lindgren, J., see Tiiman, A. (3) 971–982
 Lindsay, S., see Jenkins, A. (3) 1169–1182
 Ling, W., see Li, Y. (1) 135–148
 Linnartz, C., see Hülsemann, M. (1) 79–88
 Liraz, O., see Boehm-Cagan, A. (3) 1219–1233
 Lisetti, V., see Chiasserini, D. (1) 55–67
 Liu, B., see Hakobyan, S. (2) 707–716
 Liu, D., see Yuan, B. (4) 1409–1423
 Liu, E., see Brody, M. (4) 1509–1519
 Liu, J., see Li, Y. (1) 135–148
 Liu, S., Y.-T. Ong, S. Hilal, Y.M. Loke, T.Y. Wong, C.L.-H. Chen, C.Y. Cheung and J. Zhou, The Association Between Retinal Neuronal Layer and Brain Structure is Disrupted in Patients with Cognitive Impairment and Alzheimer's Disease (2) 585–595
 Llorens, F., see Karch, A. (4) 1385–1393

- Lo, R.Y., see Ren, P. (1) 69–78
 Loewenstein, D.A., see Curiel, R.E. (2) 793–799
 Loke, Y.M., see Liu, S. (2) 585–595
 Lombardi, V.C., see Mukhamedyarov, M.A. (4) 1373–1383
 Londos, E., see van Steenoven, I. (1) 287–295
 López de Cerain, A., see Bengoetxea, X. (3) 1085–1094
 López, L., see Villarreal, A.E. (3) 897–901
 López-González, I., A. Palmeira, E. Aso, M. Carmo-
 na, L. Fernandez and I. Ferrer, FOXP2 Expression
 in Frontotemporal Lobar Degeneration-
 Tau (2) 471–475
 Lou, W., L. Shi, A. Wong, W.C.W. Chu, V.C.T. Mok
 and D. Wang, Changes of Cerebral Perfusion
 and Functional Brain Network Organization in
 Patients with Mild Cognitive Impairment (1)
 397–409
 Lovestone, S., see Hakobyan, S. (2) 707–716
 Lozano, A.M., L. Fosdick, M.M. Chakravarty,
 J.-M. Leoutsakos, C. Munro, E. Oh, K.E. Drake,
 C.H. Lyman, P.B. Rosenberg, W.S. Anderson,
 D.F. Tang-Wai, J.C. Pendergrass, S. Salloway,
 W.F. Asaad, F.A. Ponce, A. Burke, M. Sabbagh,
 D.A. Wolk, G. Baltuch, M.S. Okun, K.D. Foote,
 M.P. McAndrews, P. Giacobbe, S.D. Targum,
 C.G. Lyketsos and G.S. Smith, A Phase II Study
 of Fornix Deep Brain Stimulation in Mild Al-
 zheimer's Disease (2) 777–787
 Lu, C.Y., see Tan, E.C.K. (4) 1425–1435
 Lu, M., see Brody, M. (4) 1509–1519
 Luccarini, I., D. Pantano, P. Nardiello, L. Cavone,
 A. Lapucci, C. Miceli, C. Nediani, A. Berti, M.
 Stefani and F. Casamenti, The Polyphenol Oleu-
 ropein Aglycone Modulates the PARP1-SIRT1
 Interplay: An In Vitro and In Vivo Study (2)
 737–750
 Luck, T., see Wolfsgruber, S. (3) 1135–1146
 Lühmann, D., see Heser, K. (1) 185–199
 Lühmann, D., see Wolfsgruber, S. (3) 1135–1146
 Lühmann, N., see Hülsemann, M. (1) 79–88
 Lunn, M.P., see Westona, P.S.J. (4) 1297–1302
 Luo, J., see Tiiman, A. (3) 971–982
 Luo, X., see Qiu, T. (4) 1483–1493
 Luyckx, J., see Somers, C. (1) 383–395
 Lyketsos, C.G., see Lozano, A.M. (2) 777–787
 Lyman, C.H., see Lozano, A.M. (2) 777–787
 Ma, T., see Beckelman, B.C. (2) 669–678
 Mabondzo, A., see Portelius, E. (4) 1593–1605
 Macfarlane, S., see Malpas, C.B. (1) 223–232
 Magnani, G., see Mazzeo, S. (4) 1495–1508
 Magnin, E., J.-F. Démonet, D. Wallon, J. Dumurgier,
 A.-C. Troussière, A. Jager, E. Duron, A. Ga-
 belle, V. de la Sayette, L. Volpe-Gillot, G. Tio,
 S. Evain, C. Boutoleau-Bretonnière, A. Ender-
 le, F. Mouton-Liger, P. Robert, D. Hannequin,
 F. Pasquier, J. Hugon, C. Paquet and on behalf
 of ePLM collaborators, Primary Progressive
 Aphasia in the Network of French Alzheimer
 Plan Memory Centers (4) 1459–1471
 Mahringer, C., see Struhala, W. (2) 657–667
 Maier, W., see Gomm, W. (2) 801–808
 Maier, W., see Heser, K. (1) 185–199
 Maier, W., see Wolfsgruber, S. (3) 1135–1146
 Makarov, A.A., see Khmeleva, S.A. (2) 809–819
 Makarov, A.A., see Morozov, A.V. (2) 763–776
 Makino, K., see Makizako, H. (4) 1473–1482
 Makizako, H., H. Shimada, T. Doi, K. Tsutsumimoto,
 R. Hotta, S. Nakakubo, K. Makino and T. Suzuki,
 Comorbid Mild Cognitive Impairment and
 Depressive Symptoms Predict Future Dementia
 in Community Older Adults: A 24-Month
 Follow-Up Longitudinal Study (4) 1473–1482
 Malpas, C.B., L. Vivash, S. Genc, M.M. Saling, P.
 Desmond, C. Steward, R.J. Hicks, J. Callahan,
 A. Brodtmann, S. Collins, S. Macfarlane, N.M.
 Corcoran, C.M. Hovens, D. Velakoulis and T.J.
 O'Brien, A Phase IIa Randomized Control Trial
 of VEL015 (Sodium Selenate) in Mild-Moder-
 ate Alzheimer's Disease (1) 223–232
 Mamone, S., see Heser, K. (1) 185–199
 Mancuso, L., see Gertje, E.C. (3) 1027–1037
 Mandecka, M., M. Budziszewska, A. Barczak, B.
 Peplńska, M. Chodakowska-Żebrowska,
 A. Filipiek-Gliszczyńska, M. Nesteruk, M.
 Styczyńska, M. Barcikowska and T. Gabryele-
 wicz, Association between Cerebrospinal Fluid
 Biomarkers for Alzheimer's Disease, APOE
 Genotypes and Auditory Verbal Learning Task
 in Subjective Cognitive Decline, Mild Cogni-
 tive Impairment, and Alzheimer's Disease (1)
 157–168
 Mander, A., see Connors, M.H. (1) 149–155
 Manousopoulou, A., see Portelius, E. (4) 1593–1605
 Mapstone, M., see Ren, P. (1) 69–78
 Maras, B., see Martire, S. (1) 307–324
 Marchenkov, V.V., see Selivanova, O.M. (2) 821–830
 Marchesi, N., M. Amadio, C. Colombrita, S. Govoni,
 A. Ratti and A. Pascale, PKC Activation Coun-
 teracts ADAM10 Deficit in HuD-Silenced Neu-
 roblastoma Cells (2) 535–547
 Maresova, P., B. Klimova, M. Novotny and K.
 Kuca, Alzheimer's and Parkinson's Diseases:

- Expected Economic Impact on Europe—A Call for a Uniform European Strategy (3) 1123–1133
- Margolin, R.A., see Brody, M. (4) 1509–1519
- Mari, D., see Arosio, B. (2) 417–425
- Martin, C.K., see Myers, C.A. (4) 1359–1364
- Martin, J.-J., see Somers, C. (1) 383–395
- Martinez, A., see Santamaría-García, H. (3) 957–970
- Martínez-Martínez, L., see Calderón-Garcidueñas, L. (2) 597–613
- Martire, S., A. Fusco, L. Mosca, E. Forte, V. Correani, M. Fontana, S. Scarpa, B. Maras and M. d’Erme, Bioenergetic Impairment in Animal and Cellular Models of Alzheimer’s Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions (1) 307–324
- Marugan, J., see Estrada, L.D. (3) 1193–1205
- Matallana, D., see Santamaría-García, H. (3) 957–970
- Matsumoto, S., see Hara, H. (3) 1047–1059
- Matsunaga, S., T. Kishi and N. Iwata, Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials (2) 635–643
- Mäurer, A., see Ritter, K. (4) 1319–1331
- Mazzeo, S., R. Santangelo, M.P. Bernasconi, G. Cecchetti, A. Fiorino, P. Pinto, G. Passerini, M. Falautano, G. Comi and G. Magnani, Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia (4) 1495–1508
- McAndrews, M.P., see Lozano, A.M. (2) 777–787
- McClure, L.A., see Cushman, M. (2) 497–503
- McCully, K.S., Homocysteine, Infections, Polyamines, Oxidative Metabolism, and the Pathogenesis of Dementia and Atherosclerosis (4) 1283–1290
- McGeer, E.G., see McGeer, P.L. (3) 853–857
- McGeer, P.L., J. Rogers and E.G. McGeer, Inflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years (3) 853–857
- Mead, E., D. Kestoras, Y. Gibson, L. Hamilton, R. Goodson, S. Jones, S. Eversden, P. Davies, M. O’Neill, M. Hutton, P. Szekeres and J. Wolak, Halting of Caspase Activity Protects Tau from MC1-Conformational Change and Aggregation (4) 1521–1538
- Mechanic-Hamilton, D., see Roalf, D.R. (1) 325–335
- Meditskos, G., see Lazarou, I. (4) 1561–1591
- Meijer, L., see Portelius, E. (4) 1593–1605
- Mende, C., see Ritter, K. (4) 1319–1331
- Mesulam, M.-M., see Guo, L. (3) 1157–1167
- Meurs, E.F., see Gourmaud, S. (4) 1659–1670
- Mezentsev, Y.V., see Khmeleva, S.A. (2) 809–819
- Miceli, C., see Luccarini, I. (2) 737–750
- Michaelson, D.M., see Boehm-Cagan, A. (3) 1219–1233
- Middelstädt, J., A.-K. Folkerts, S. Blawath and E. Kalbe, Cognitive Stimulation for People with Dementia in Long-Term Care Facilities: Baseline Cognitive Level Predicts Cognitive Gains, Moderated by Depression (1) 253–268
- Midorikawa, A., C.E. Leyton, D. Foxe, R. Landin-Romero, J.R. Hodges and O. Piguet, All Is Not Lost: Positive Behaviors in Alzheimer’s Disease and Behavioral-Variant Frontotemporal Dementia with Disease Severity (2) 549–558
- Mikus, M., see Musunuri, S. (4) 1671–1686
- Mintzer, J.E., see Rosenberg, P.B. (1) 373–381
- Mirzaa, A., A. King, C. Troakes and C. Exley, The Identification of Aluminum in Human Brain Tissue Using Lumogallion and Fluorescence Microscopy (4) 1333–1338
- Mitkevich, V.A., see Khmeleva, S.A. (2) 809–819
- Mitkevich, V.A., see Morozov, A.V. (2) 763–776
- Moberg, P.J., see Roalf, D.R. (1) 325–335
- Mok, V.C.T., see Lou, W. (1) 397–409
- Mollenhauer, B., see van Steenoven, I. (1) 287–295
- Montalván, A., see Villarreal, A.E. (3) 897–901
- Montañés, M., see Pérez-Grijalba, V. (2) 751–762
- Montembeault, M., see Chapleau, M. (3) 941–955
- Moos, T., see Zakarias, J.K. (3) 1183–1192
- Morbelli, S., see Chincarini, A. (4) 1437–1457
- Morgan, B.P., see Hakobyan, S. (2) 707–716
- Mori, T., see Yoshino, Y. (4) 1349–1357
- Morley, J.E., see Farr, S.A. (4) 1339–1348
- Morozov, A.V., A.A. Kulikova, T.M. Astakhova, V.A. Mitkevich, K.M. Burnysheva, A.A. Adzhubei, P.A. Erokhov, M.B. Evgen’ev, N.P. Sharova, V.L. Karpov and A.A. Makarov, Amyloid- β Increases Activity of Proteasomes Capped with 19S and 11S Regulators (2) 763–776
- Mörzl, C., see Struhal, W. (2) 657–667
- Mosca, L., see Martire, S. (1) 307–324
- Mösch, E., see Wolfsgruber, S. (3) 1135–1146
- Mouton-Liger, F., see Gourmaud, S. (4) 1659–1670
- Mouton-Liger, F., see Magnin, E. (4) 1459–1471
- Muck, S., see Klafki, H.-W. (2) 691–705
- Mueller, K.D., R.L. Kosciak, L.S. Turkstra, S.K. Riedeman, A. LaRue, L.R. Clark, B. Hermann, M.A. Sager and S.C. Johnson, Connected

- Language in Late Middle-Aged Adults at Risk for Alzheimer's Disease (4) 1539–1550
- Mueller, K.D., see Racine, A.M. (4) 1395–1408
- Mukhamedyarov, M.A., A.A. Rizvanov, E.Z. Yakupov, A.L. Zefirov, A.P. Kiyasov, H.J. Reis, A.L. Teixeira, L.B. Vieira, L.M. Lima, I.I. Salafutdinov, E.O. Petukhova, S.F. Khaiboullina, K.A. Schlauch, V.C. Lombardi and A. Palotás, Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer's Disease (4) 1373–1383
- Mukherjee, P.S., see Calderón-Garcidueñas, L. (2) 597–613
- Mummery, C.J., see Westona, P.S.J. (4) 1297–1302
- Munro, C., see Lozano, A.M. (2) 777–787
- Musa, G., see Bertoux, M. (3) 1005–1014
- Musunuri, S., P.E. Khoonsari, M. Mikus, M. Wetterhall, A. Häggmark-Månberg, L. Lannfelt, A. Erlandsson, J. Bergquist, M. Ingelsson, G. Shevchenko, P. Nilsson and K. Kultima, Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer's Disease Brain (4) 1671–1686
- Myers, C.A., J.N. Keller, H.R. Allen, R.M. Brouillette, H. Foil, A.B. Davis, F.L. Greenway, W.D. Johnson and C.K. Martin, Reliability and Validity of a Novel Internet-Based Battery to Assess Mood and Cognitive Function in the Elderly (4) 1359–1364
- Na, D.L., see Noh, Y. (3) 1015–1026
- Nagaraja, H.N., see Scharre, D.W. (3) 995–1004
- Nagele, R.G., see Goldwasser, E.L. (2) 445–456
- Nakakubo, S., see Makizako, H. (4) 1473–1482
- Nakamura, S., see Hara, H. (3) 1047–1059
- Nardiello, P., see Luccarini, I. (2) 737–750
- Nascimento, C.F., see Grinberg, L.T. (1) 169–174
- Naslavsky, M.S., see Grinberg, L.T. (1) 169–174
- Nediani, C., see Luccarini, I. (2) 737–750
- Nesteruk, M., see Mandacka, M. (1) 157–168
- Nicholas, C.R., see Racine, A.M. (4) 1395–1408
- Niehoff, M.L., see Farr, S.A. (4) 1339–1348
- Nielsen, T.R., see Stevnsborg, L. (2) 505–514
- Niemantsverdriet, E., see Somers, C. (1) 383–395
- Nilsson, P., see Musunuri, S. (4) 1671–1686
- Nitrini, R., see Grinberg, L.T. (1) 169–174
- Nobili, F., see Bonanni, L. (4) 1649–1657
- Nobili, F., see Chincarini, A. (4) 1437–1457
- Noh, Y., S.W. Seo, S. Jeon, J.M. Lee, J.S. Kim, J.-H. Lee, J.-H. Kim, G.H. Kim, B.S. Ye, H. Cho, H.J. Kim, C.W. Yoon, Y.S. Choe, K.-H. Lee, M.W. Weiner and D.L. Na, The Role of Cerebrovascular Disease in Amyloid Deposition (3) 1015–1026
- Nørgaard, A., see Zakarias, J.K. (3) 1183–1192
- Norton, D., see Racine, A.M. (4) 1395–1408
- Novak, G., see Brody, M. (4) 1509–1519
- Novak, M., see Zimova, I. (2) 831–843
- Novotny, M., see Maresova, P. (3) 1123–1133
- Núñez, L., see Calvo-Rodríguez, M. (1) 207–221
- O' Hara, R., see Durazzo, T.C. (1) 99–107
- O'Brien, T.J., see Malpas, C.B. (1) 223–232
- O'Bryant, S.E., see Johnson, L.A. (1) 201–206
- O'Bryant, S.E., see Villarreal, A.E. (3) 897–901
- O'Neill, M., see Mead, E. (4) 1521–1538
- Oh, E., see Lozano, A.M. (2) 777–787
- Okun, M.S., see Lozano, A.M. (2) 777–787
- Olsen, I., and S.K. Singhrao, Inflammasome Involvement in Alzheimer's Disease (1) 45–53
- Olsson, L., see Tiiman, A. (3) 971–982
- Omori, C., see Portelius, E. (4) 1593–1605
- Onesti, E., see Trebbastoni, A. (3) 1039–1045
- Ong, Y.-T., see Liu, S. (2) 585–595
- Ono, F., see Hara, H. (3) 1047–1059
- Onofrj, M., see Bonanni, L. (4) 1649–1657
- Ordoñez-Gutierrez, L., I. Fernandez-Perez, J.L. Herrera, M. Anton, I. Benito-Cuesta and F. Wandosell, A β PP/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging (2) 645–656
- Oumata, N., see Portelius, E. (4) 1593–1605
- Ozaki, Y., see Yoshino, Y. (4) 1349–1357
- Padovani, A., see Chincarini, A. (4) 1437–1457
- Pallas, M., see Ettcheto, M. (1) 233–251
- Palmeira, A., see López-González, I. (2) 471–475
- Palotás, A., see Mukhamedyarov, M.A. (4) 1373–1383
- Pannee, J., see Portelius, E. (4) 1593–1605
- Pant, H.C., see Binukumar, B.K. (2) 525–533
- Pantano, D., see Luccarini, I. (2) 737–750
- Paquet, C., see Gourmaud, S. (4) 1659–1670
- Paquet, C., see Magnin, E. (4) 1459–1471
- Parham, C.L., C. Shaw, L.D. Auckland, S.K. Dickerson, I. Griswold-Prenner and G. Bix, Perlecan Domain V Inhibits Amyloid- β Induced Activation of the α 2 β 1 Integrin-Mediated Neurotoxic Signaling Cascade (4) 1629–1647
- Park, A., see Scharre, D.W. (3) 995–1004
- Park, S.H., see Seo, E.H. (2) 559–568
- Parkington, H.C., see Kuruppu, S. (3) 891–895
- Parnetti, L., see Chiasserini, D. (1) 55–67
- Pascale, A., see Marchesi, N. (2) 535–547

- Pasinetti, G.M., see Varghese, M. (2) 477–496
 Pasqualucci, C.A., see Grinberg, L.T. (1) 169–174
 Pasquier, F., see Magnin, E. (4) 1459–1471
 Passerini, G., see Mazzeo, S. (4) 1495–1508
 Paterson, R.W., see Westona, P.S.J. (4) 1297–1302
 Paxinos, G., see Fu, Y.H. (2) 569–584
 Pedrós, I., see Ettcheto, M. (1) 233–251
 Pelech, S.L., see Binukumar, B.K. (2) 525–533
 Pellegrino, G., see Tombini, M. (4) 1619–1627
 Pelleieux, S., see De Beaumont, L. (3) 913–922
 Pendergrass, J.C., see Lozano, A.M. (2) 777–787
 Pentzek, M., see Hesper, K. (1) 185–199
 Pentzek, M., see Wolfsgruber, S. (3) 1135–1146
 Peplowska, B., see Manddecka, M. (1) 157–168
 Pereira, M.G., see Lima, S. (3) 1113–1121
 Pérez-Grijalba, V., N. Fandos, J. Canudas, D. Insua, D. Casabona, A.M. Lacosta, M. Montañés, P. Pesini and M. Sarasa, Validation of Immunoassay-Based Tools for the Comprehensive Quantification of A β_{40} and A β_{42} Peptides in Plasma (2) 751–762
 Pesini, P., see Pérez-Grijalba, V. (2) 751–762
 Peters, L., see Hülsemann, M. (1) 79–88
 Peters, O., see Ritter, K. (4) 1319–1331
 Petniak, A., see Ułamek-Kozioł, M. (1) 113–121
 Petrella, R.J., see Heath, M. (3) 923–931
 Petrov, D., see Ettcheto, M. (1) 233–251
 Petukhova, E.O., see Mukhamedyarov, M.A. (4) 1373–1383
 Piguet, O., see Midorikawa, A. (2) 549–558
 Pinto, P., see Mazzeo, S. (4) 1495–1508
 Pluta, J., see Gertje, E.C. (3) 1027–1037
 Pluta, R., see Ułamek-Kozioł, M. (1) 113–121
 Poirier, J., see De Beaumont, L. (3) 913–922
 Polanco, J.C., see Baker, S. (3) 1207–1217
 Ponce, F.A., see Lozano, A.M. (2) 777–787
 Porsteinsson, A., see Ren, P. (1) 69–78
 Porsteinsson, A.P., see Rosenberg, P.B. (1) 373–381
 Portelius, E., E. Durieu, M. Bodin, M. Cam, J. Pannee, C. Leuxe, A. Mabondzo, N. Oumata, H. Galons, J.Y. Lee, Y.-T. Chang, K. Stüber, P. Koch, G. Fontaine, M.-C. Potier, A. Manousopoulou, S.D. Garbis, A. Covaci, D. Van Dam, P. De Deyn, F. Karg, M. Flajolet, C. Omori, S. Hata, T. Suzuki, K. Blennow, H. Zetterberg and L. Meijer, Specific Triazine Herbicides Induce Amyloid- β_{42} Production (4) 1593–1605
 Posselt, T., see Hesper, K. (1) 185–199
 Potier, M.-C., see Portelius, E. (4) 1593–1605
 Prasad, V., see Ritter, K. (4) 1319–1331
 Qiu, T., X. Luo, Z. Shen, P. Huang, X. Xu, J. Zhou, M. Zhang and for the Alzheimer's Disease Neuroimaging Initiative, Disrupted Brain Network in Progressive Mild Cognitive Impairment Measured by Eigenvector Centrality Mapping is Linked to Cognition and Cerebrospinal Fluid Biomarkers (4) 1483–1493
 Quarmley, M., see Roalf, D.R. (1) 325–335
 Racine, A.M., L.R. Clark, S.E. Berman, R.L. Kosciak, K.D. Mueller, D. Norton, C.R. Nicholas, K. Blennow, H. Zetterberg, B. Jedynak, M. Bilgel, C.M. Carlsson, B.T. Christian, S. Asthana and S.C. Johnson, Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease (4) 1395–1408
 Radko, S.P., see Khmeleva, S.A. (2) 809–819
 Raffo, A., see Curiel, R.E. (2) 793–799
 Rahimpour, S., see Tiiman, A. (3) 971–982
 Rai, N., R. Kumar, G.R. Desai, G. Venugopalan, S. Shekhar, P. Chatterjee, M. Tripathi, A.D. Upadhyay, S. Dwivedi, A.B. Dey and S. Dey, Relative Alterations in Blood-Based Levels of Sestrin in Alzheimer's Disease and Mild Cognitive Impairment Patients (3) 1147–1155
 Rajapakse, N.W., see Kuruppu, S. (3) 891–895
 Raman, R., see Rosenberg, P.B. (1) 373–381
 Ramanan, S., see Bertoux, M. (3) 1005–1014
 Ramirez, M.J., see Bengoetxea, X. (3) 1085–1094
 Ransmayr, G., see Struhal, W. (2) 657–667
 Ratti, A., see Marchesi, N. (2) 535–547
 Rei, L., see Chincarini, A. (4) 1437–1457
 Reis, H.J., see Mukhamedyarov, M.A. (4) 1373–1383
 Reis, J., see Calderón-Garcidueñas, L. (2) 597–613
 Ren, P., R.Y. Lo, B.P. Chapman, M. Mapstone, A. Porsteinsson, F. Lin and the Alzheimer's Disease Neuroimaging Initiative, Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment (1) 69–78
 Renard, D., A. Gabelle, C. Hirtz, C. Demattei, E. Thouvenot and S. Lehmann, Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis (4) 1291–1295
 Reñé-Ramírez, R., see Turró-Garriga, O. (4) 1551–1560
 Reyes, P., see Santamaría-García, H. (3) 957–970

- Rezvanian, A., see Guo, L. (3) 1157–1167
- Riedel-Heller, S.G., see Hesper, K. (1) 185–199
- Riedel-Heller, S.G., see Wolfsgruber, S. (3) 1135–1146
- Riedeman, S.K., see Mueller, K.D. (4) 1539–1550
- Rinne, J., see Iso-Markku, P. (4) 1303–1317
- Ritter, K., C. Lange, M. Weygandt, A. Mäurer, A. Roberts, M. Estrella, P. Suppa, L. Spies, V. Prasad, I. Steffen, I. Apostolova, D. Bittner, M. Gövercin, W. Brenner, C. Mende, O. Peters, J. Seybold, J.B. Fiebach, E. Steinhagen-Thiessen, H. Hampel, J.-D. Haynes and R. Buchert, Combination of Structural MRI and FDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients (4) 1319–1331
- Rizvanov, A.A., see Mukhamedyarov, M.A. (4) 1373–1383
- Roalf, D.R., M. Quarmley, D. Mechanic-Hamilton, D.A. Wolk, S.E. Arnold, P.J. Moberg and for the Alzheimer's Disease Neuroimaging Initiative, Within-Individual Variability: An Index for Subtle Change in Neurocognition in Mild Cognitive Impairment (1) 325–335
- Robert, P., see Magnin, E. (4) 1459–1471
- Roberts, A., see Ritter, K. (4) 1319–1331
- Rogers, J., see McGeer, P.L. (3) 853–857
- Roos, P., see Tiiman, A. (3) 971–982
- Roose, D., see Blockx, I. (2) 723–735
- Rosado, M., see Curiel, R.E. (2) 793–799
- Roselli, F., see Li, Y. (1) 135–148
- Rosenberg, P.B., K.L. Lancôt, N. Herrmann, J.E. Mintzer, A.P. Porsteinsson, X. Sun and R. Raman, Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease (1) 373–381
- Rosenberg, P.B., see Lozano, A.M. (2) 777–787
- Rossi, P.D., see Arosio, B. (2) 417–425
- Rossor, M.N., see Westona, P.S.J. (4) 1297–1302
- Ruiz-Ramos, R., see Calderón-Garcidueñas, L. (2) 597–613
- Sabbagh, M., see Lozano, A.M. (2) 777–787
- Sager, M.A., see Mueller, K.D. (4) 1539–1550
- Salafutdinov, I.I., see Mukhamedyarov, M.A. (4) 1373–1383
- Saling, M.M., see Malpas, C.B. (1) 223–232
- Salloway, S., see Lozano, A.M. (2) 777–787
- Salvadori, N., see Chiasserini, D. (1) 55–67
- Samarasinghe, K., see Wijesinghe, P. (4) 1607–1618
- Sandoval, K.E., see Farr, S.A. (4) 1339–1348
- Santacruz, J.M., see Santamaría-García, H. (3) 957–970
- Santa-Maria, I., see Varghese, M. (2) 477–496
- Santamaría-García, H., P. Reyes, A. García, S. Baéz, A. Martínez, J.M. Santacruz, A. Slachevsky, M. Sigman, D. Matallana and A. Ibañez, First Symptoms and Neurocognitive Correlates of Behavioral Variant Frontotemporal Dementia (3) 957–970
- Santangelo, R., see Mazzeo, S. (4) 1495–1508
- Sao, T., see Yoshino, Y. (4) 1349–1357
- Sarasa, M., see Pérez-Grijalba, V. (2) 751–762
- Sarazin, M., see Bertoux, M. (3) 1005–1014
- Sarkar, A., see Goldwaser, E.L. (2) 445–456
- Scarpa, S., see Martire, S. (1) 307–324
- Scarpini, E., see Cioffi, S.M.G. (2) 717–721
- Scharre, D.W., S.-I. Chang, H.N. Nagaraja, A. Park, A. Adeli, P. Agrawal, A. Kloos, D. Kegelmeyer, S. Linder, N. Fritz, S.K. Kostyk and M. Katakai, Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer's and Parkinson's Diseases (3) 995–1004
- Scherbaum, N., see Klafki, H.-W. (2) 691–705
- Scherer, M., see Hesper, K. (1) 185–199
- Scherer, M., see Wolfsgruber, S. (3) 1135–1146
- Schlauch, K.A., see Mukhamedyarov, M.A. (4) 1373–1383
- Schmidt, C., see Karch, A. (4) 1385–1393
- Schmitz, M., see Karch, A. (4) 1385–1393
- Schott, J.M., see Westona, P.S.J. (4) 1297–1302
- Schuchhardt, J., see Klafki, H.-W. (2) 691–705
- Scortichini, V., see Arosio, B. (2) 417–425
- Selivanova, O.M., A.K. Surin, V.V. Marchenkov, U.F. Dzhus, E.I. Grigorashvili, M.Y. Suvorina, A.V. Glyakina, N.V. Dovidchenko and O.V. Galzitskaya, The Mechanism Underlying Amyloid Polymorphism is Opened for Alzheimer's Disease Amyloid- β Peptide (2) 821–830
- Sensi, F., see Chincarini, A. (4) 1437–1457
- Seo, E.H., H. Kim, K.H. Lee and I.H. Choo, Altered Executive Function in Pre-Mild Cognitive Impairment (3) 933–940
- Seo, E.H., S.H. Kim, S.H. Park, S.-H. Kang, I.H. Choo and for the Alzheimer's Disease Neuroimaging Initiative, Topographical APOE $\epsilon 4$ Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis (2) 559–568
- Seo, S.W., see Noh, Y. (3) 1015–1026
- Sepe-Monti, M., N. Vanacore, L. Bartorelli, A. Tognetti, F. Giubilei and Savvy Caregiver Study Group, The Savvy Caregiver Program: A Probe Multicenter Randomized Controlled Pilot Trial in Caregivers of Patients Affected by Alzheimer's Disease (3) 1235–1246

- Serpente, M., see Cioffi, S.M.G. (2) 717–721
- Seybold, J., see Ritter, K. (4) 1319–1331
- Shadman, A., see Brody, M. (4) 1509–1519
- Shankar, S.K., see Wijesinghe, P. (4) 1607–1618
- Shankle, W.R., J. Hara, L.W. Barrentine and M.V. Curole, CerefolinNAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer's Disease and Cerebrovascular Disease (3) 1073–1084
- Sharova, N.P., see Morozov, A.V. (2) 763–776
- Shaw, C., see Parham, C.L. (4) 1629–1647
- Shaw, L.M., see Durazzo, T.C. (1) 99–107
- Shekhar, S., see Rai, N. (3) 1147–1155
- Shen, D., see Zhang, H. (3) 1095–1112
- Shen, Z., see Qiu, T. (4) 1483–1493
- Shevchenko, G., see Musunuri, S. (4) 1671–1686
- Shi, F., see Zhang, H. (3) 1095–1112
- Shi, L., see Lou, W. (1) 397–409
- ShiDu Yan, S., see Yu, Q. (2) 679–690
- Shimada, H., see Makizako, H. (4) 1473–1482
- Sholts, S.B., see Tiiman, A. (3) 971–982
- Shu, H., see Chen, G. (3) 983–993
- Shu, H., see Yuan, B. (4) 1409–1423
- Shukla, V., see Binukumar, B.K. (2) 525–533
- Sicari, M., see Tombini, M. (4) 1619–1627
- Sigman, M., see Santamaría-García, H. (3) 957–970
- Sinakos, Z., see Tsolaki, M. (1) 129–133
- Singh Rao S.K., see Olsen, I. (1) 45–53
- Skuntz, S., see Binukumar, B.K. (2) 525–533
- Slachevsky, A., see Bertoux, M. (3) 1005–1014
- Slachevsky, A., see Santamaría-García, H. (3) 957–970
- Smith, A.I., see Kuruppu, S. (3) 891–895
- Smith, G.S., see Lozano, A.M. (2) 777–787
- Smolek, T., see Zimova, I. (2) 831–843
- Somers, C., H. Struyfs, J. Goossens, E. Niemantsverdriet, J. Luyckx, N. De Roeck, E. De Roeck, B. De Vil, P. Cras, J.-J. Martin, P.-P. De Deyn, M. Bjerke and S. Engelborghs, A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium (1) 383–395
- Song, Y., see Li, Y. (1) 135–148
- Soto, C., see Estrada, L.D. (3) 1193–1205
- Spallazzi, M., see Cioffi, S.M.G. (2) 717–721
- Spicer, A.J., see Kuruppu, S. (3) 891–895
- Spies, L., see Ritter, K. (4) 1319–1331
- Stavropoulos, T.G., see Lazarou, I. (4) 1561–1591
- Stefani, M., see Luccarini, I. (2) 737–750
- Steffen, I., see Ritter, K. (4) 1319–1331
- Stein, J., see Hesar, K. (1) 185–199
- Stein, J., see Wolfsgruber, S. (3) 1135–1146
- Steinbusch, H.W.M., see Wijesinghe, P. (4) 1607–1618
- Steiner, J., see Binukumar, B.K. (2) 525–533
- Steinhagen-Thiessen, E., see Ritter, K. (4) 1319–1331
- Steinmann, S., see Wolfsgruber, S. (3) 1135–1146
- Stevnsborg, L., C. Jensen-Dahm, T.R. Nielsen, C. Gasse and G. Waldemar, Inequalities in Access to Treatment and Care for Patients with Dementia and Immigrant Background: A Danish Nationwide Study (2) 505–514
- Stevnsborg, L., see Zakarias, J.K. (3) 1183–1192
- Steward, C., see Malpas, C.B. (1) 223–232
- Stoops, E., see Chiasserini, D. (1) 55–67
- Struhal, W., C. Mahringer, H. Lahrman, C. Mörtl, P. Buhl, M. Huemer and G. Ransmayr, Heart Rate Spectra Confirm the Presence of Autonomic Dysfunction in Dementia Patients (2) 657–667
- Struyfs, H., see Somers, C. (1) 383–395
- Stüber, K., see Portelius, E. (4) 1593–1605
- Styczyńska, M., see Mandecka, M. (1) 157–168
- Su, J., see Li, D. (1) 89–98
- Suh, Y.-H., see Kang, J.M. (3) 879–889
- Suh, Y.-h., see Wijesinghe, P. (4) 1607–1618
- Sun, H., see Sun, J. (1) 175–184
- Sun, J., R. Cai, R. Huang, P. Wang, S. Tian, H. Sun, W. Xia and S. Wang, Cholesteryl Ester Transfer Protein Intimately Involved in Dyslipidemia-Related Susceptibility to Cognitive Deficits in Type 2 Diabetic Patients (1) 175–184
- Sun, X., see Rosenberg, P.B. (1) 373–381
- Suppa, P., see Ritter, K. (4) 1319–1331
- Surin, A.K., see Selivanova, O.M. (2) 821–830
- Sutter, C., see Binukumar, B.K. (2) 525–533
- Suvorina, M.Y., see Selivanova, O.M. (2) 821–830
- Suzuki, T., see Makizako, H. (4) 1473–1482
- Suzuki, T., see Portelius, E. (4) 1593–1605
- Swerdlow, R.H., see Yu, Q. (2) 679–690
- Szekeres, P., see Mead, E. (4) 1521–1538
- Tabira, T., see Hara, H. (3) 1047–1059
- Taheri, S., J. Yu, H. Zhu and M.S. Kindy, High-Sodium Diet Has Opposing Effects on Mean Arterial Blood Pressure and Cerebral Perfusion in a Transgenic Mouse Model of Alzheimer's Disease (3) 1061–1072
- Takada, L.T., see Grinberg, L.T. (1) 169–174
- Tales, A., see Jenkins, A. (3) 1169–1182
- Tan, E.C.K., J.S. Bell, C.Y. Lu and S. Toh, National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States (4) 1425–1435
- Tang-Wai, D.F., see Lozano, A.M. (2) 777–787
- Targum, S.D., see Lozano, A.M. (2) 777–787
- Taylor, J.-P., see Bonanni, L. (4) 1649–1657

- Teixeira, A.L., see Mukhamedyarov, M.A. (4) 1373–1383
- Teunissen, C.E., see van Steenoven, I. (1) 287–295
- Thacker, E.L., see Cushman, M. (2) 497–503
- Thomé, F., see Gomm, W. (2) 801–808
- Thompson, C., see Calderón-Garcidueñas, L. (2) 597–613
- Thornton, I.M., see Jenkins, A. (3) 1169–1182
- Thouvenot, E., see Renard, D. (4) 1291–1295
- Tian, S., see Sun, J. (1) 175–184
- Tierney, M.C., see Jaakkimainen, R.L. (1) 337–349
- Tiiman, A., J. Luo, C. Wallin, L. Olsson, J. Lindgren, J. Jarvet, P. Roos, S.B. Sholts, S. Rahimipour, J.P. Abrahams, A.E. Karlström, A. Gräslund and S.K.T.S. Wärmländer, Specific Binding of Cu(II) Ions to Amyloid-Beta Peptides Bound to Aggregation-Inhibiting Molecules or SDS Micelles Creates Complexes that Generate Radical Oxygen Species (3) 971–982
- Tio, G., see Magnin, E. (4) 1459–1471
- Tognetti, A., see Sepe-Monti, M. (3) 1235–1246
- Toh, S., see Tan, E.C.K. (4) 1425–1435
- Tombini, M., M. Sicari, G. Pellegrino, F. Ursini, P. Insardá and V. Di Lazzaro, Nutritional Status of Patients with Alzheimer's Disease and Their Caregivers (4) 1619–1627
- Torres-Jardón, R., see Calderón-Garcidueñas, L. (2) 597–613
- Trebbastoni, A., F. D'Antonio, C. de Lena, E. Onesti, B. John and M. Inghilleri, Primary Progressive Orofacial Apraxia: A Ten-Year Long Follow-Up Case Report (3) 1039–1045
- Tripathi, M., see Rai, N. (3) 1147–1155
- Troakes, C., see Mirzaa, A. (4) 1333–1338
- Trojanowski, J.Q., see Durazzo, T.C. (1) 99–107
- Troussière, A.-C., see Magnin, E. (4) 1459–1471
- Trumbore, C.N., Shear-Induced Amyloid Formation in the Brain: I. Potential Vascular and Parenchymal Processes (2) 457–470
- Tsolaki, A., see Tsolaki, M. (1) 129–133
- Tsolaki, M., E. Karathanasi, I. Lazarou, K. Dovas, E. Verykoui, A. Karakostas, K. Georgiadis, A. Tsolaki, K. Adam, I. Kompatsiaris and Z. Sinakos, Efficacy and Safety of Crocus sativus L. in Patients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial (1) 129–133
- Tsolaki, M., see Lazarou, I. (4) 1561–1591
- Tsompanidis, T., see Lazarou, I. (4) 1561–1591
- Tsoy, E., see Levy, B. (4) 1259–1272
- Tsutsumimoto, K., see Makizako, H. (4) 1473–1482
- Tu, K., see Jaakkimainen, R.L. (1) 337–349
- Turkstra, L.S., see Mueller, K.D. (4) 1539–1550
- Turró-Garriga, O., J. Garre-Olmo, R. Reñé-Ramírez, L. Calvó-Perxas, J. Gascón-Bayarri and J.-L. Conde-Sala, Consequences of Anosognosia on the Cost of Caregivers' Care in Alzheimer's Disease (4) 1551–1560
- Ueno, S.-i., see Yoshino, Y. (4) 1349–1357
- Ułamek-Kozioł, M., J. Kocki, A. Bogucka-Kocka, A. Petniak, P. Gil-Kulik, S. Januszewski, J. Bogucki, M. Jabłoński, W. Furmaga-Jabłońska, J. Brzozowska, S.J. Czuczwar and R. Pluta, Dysregulation of Autophagy, Mitophagy, and Apoptotic Genes in the Medial Temporal Lobe Cortex in an Ischemic Model of Alzheimer's Disease (1) 113–121
- Unverzagt, F.W., see Cushman, M. (2) 497–503
- Upadhyay, A.D., see Rai, N. (3) 1147–1155
- Ursini, F., see Tombini, M. (4) 1619–1627
- Valachova, B., see Zimova, I. (2) 831–843
- Van Dam, D., see Portelius, E. (4) 1593–1605
- van der Flier, W.M., see van Steenoven, I. (1) 287–295
- Van der Linden, A., see Blockx, I. (2) 723–735
- van Steenoven, I., D. Aarsland, D. Weintraub, E. Londos, F. Blanc, W.M. van der Flier, C.E. Teunissen, B. Mollenhauer, T. Fladby, M.G. Kramberger, L. Bonanni, A.W. Lemstra and on behalf of the EuropeanDLB consortium, Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort (1) 287–295
- Vanacore, N., see Sepe-Monti, M. (3) 1235–1246
- Vanderstichele, H., see Chiasserini, D. (1) 55–67
- Varghese, M., I. Santa-Maria, L. Ho, L. Ward, S. Yemul, L. Dubner, H. Książak-Reding and G.M. Pasinetti, Extracellular Tau Paired Helical Filaments Differentially Affect Tau Pathogenic Mechanisms in Mitotic and Post-Mitotic Cells: Implications for Mechanisms of Tau Propagation in the Brain (2) 477–496
- Velakoulis, D., see Malpas, C.B. (1) 223–232
- Venugopalan, G., see Rai, N. (3) 1147–1155
- Verhoye, M., see Blockx, I. (2) 723–735
- Verykoui, E., see Tsolaki, M. (1) 129–133
- Vieira, L.B., see Mukhamedyarov, M.A. (4) 1373–1383
- Vijayan, M. and P. Hemachandra Reddy, Stroke, Vascular Dementia, and Alzheimer's Disease: Molecular Links (2) 427–443
- Villalobos, C., see Calvo-Rodríguez, M. (1) 207–221

- Villarreal, A.E., S. Grajales, S.E. O'Bryant, M. Edwards, L. López, A. Montalván and G.B. Britton for the Panama Aging Research Initiative (PARI), Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama (3) 897–901
- Vintimilla, R., see Johnson, L.A. (1) 201–206
- Vivash, L., see Malpas, C.B. (1) 223–232
- Volpe-Gillot, L., see Magnin, E. (4) 1459–1471
- von Bernhardt, R., see Estrada, L.D. (3) 1193–1205
- von Holt, K., see Gomm, W. (2) 801–808
- Vuoksimaa, E., see Iso-Markku, P. (4) 1303–1317
- Wadley, V.G., see Cushman, M. (2) 497–503
- Wagner, M., see Hesper, K. (1) 185–199
- Wagner, M., see Wolfsgruber, S. (3) 1135–1146
- Waldemar, G., see Stevnsborg, L. (2) 505–514
- Waldemar, G., see Zakarias, J.K. (3) 1183–1192
- Waldorff, F.B., see Zakarias, J.K. (3) 1183–1192
- Waller, K., see Iso-Markku, P. (4) 1303–1317
- Wallin, C., see Tiiman, A. (3) 971–982
- Wallon, D., see Magnin, E. (4) 1459–1471
- Wandosell, F., see Ordoñez-Gutierrez, L. (2) 645–656
- Wang, D., see Lou, W. (1) 397–409
- Wang, H., Y. Wang, X. Hong, S. Li and Y. Wang, Quantitative Proteomics Reveals the Mechanism of Oxygen Treatment on Lenses of Alzheimer's Disease Model Mice (1) 275–286
- Wang, P., K. Chen, L. Yao, B. Hu, X. Wu, J. Zhang, Q. Ye and X. Guo, for the Alzheimer's Disease Neuroimaging Initiative, Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares (1) 359–371
- Wang, P., see Sun, J. (1) 175–184
- Wang, S., see Sun, J. (1) 175–184
- Wang, W., see Yu, L. (1) 297–306
- Wang, Y., see Wang, H. (1) 275–286
- Wang, Y., see Wang, H. (1) 275–286
- Wang, Z., see Yuan, B. (4) 1409–1423
- Ward, B.D., see Chen, G. (3) 983–993
- Ward, J., see Connors, M.H. (1) 149–155
- Ward, L., see Varghese, M. (2) 477–496
- Wärmländer, S.K.T.S., see Tiiman, A. (3) 971–982
- Warren, J.D., see Westona, P.S.J. (4) 1297–1302
- Weckbecker, K., see Gomm, W. (2) 801–808
- Weeg, D., see Hesper, K. (1) 185–199
- Weiler, J., see Heath, M. (3) 923–931
- Weiner, M.W., see Durazzo, T.C. (1) 99–107
- Weiner, M.W., see Noh, Y. (3) 1015–1026
- Weintraub, D., see van Steenoven, I. (1) 287–295
- Weiser, B., see Johnson, L.A. (1) 201–206
- Weisova, P., see Zimova, I. (2) 831–843
- Werle, J., see Hesper, K. (1) 185–199
- Werle, J., see Wolfsgruber, S. (3) 1135–1146
- Werth, J.L., see Brody, M. (4) 1509–1519
- Westona, P.S.J., R.W. Paterson, J. Dickson, A. Barnes, J.B. Bomanji, I. Kayani, M.P. Lunn, C.J. Mummery, J.D. Warren, M.N. Rossor, N.C. Fox, H. Zetterberg and J.M. Schott, Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid? (4) 1297–1302
- Wetterhall, M., see Musunuri, S. (4) 1671–1686
- Weyerer, S., see Hesper, K. (1) 185–199
- Weyerer, S., see Wolfsgruber, S. (3) 1135–1146
- Weygandt, M., see Ritter, K. (4) 1319–1331
- Widdifield, J., see Jaakkimainen, R.L. (1) 337–349
- Wiese, B., see Hesper, K. (1) 185–199
- Wiese, B., see Wolfsgruber, S. (3) 1135–1146
- Wijesinghe, P., S.K. Shankar, T.C. Yasha, C. Gorrie, D. Amaratunga, S. Hulathduwa, K.S. Kumara, K. Samarasinghe, Y.-h. Suh, H.W.M. Steinbusch and K.R.D. De Silva, Vascular Contributions in Alzheimer's Disease-Related Neuropathological Changes: First Autopsy Evidence from a South Asian Aging Population (4) 1607–1618
- Willbold, D., see Hülsemann, M. (1) 79–88
- Willbold, J., see Hülsemann, M. (1) 79–88
- Willbold, S., see Hülsemann, M. (1) 79–88
- Willich, S.N., see Brüuggenjürgen, B. (4) 1365–1372
- Wiltfang, J., see Klafki, H.-W. (2) 691–705
- Witt, K.A., see Farr, S.A. (4) 1339–1348
- Wolak, J., see Mead, E. (4) 1521–1538
- Wolfsgruber, S., L. Kleineidam, M. Wagner, E. Mösch, H. Bickel, D. Lühmann, A. Ernst, B. Wiese, S. Steinmann, H.-H. König, C. Bretschneider, T. Luck, J. Stein, S. Weyerer, J. Werle, M. Pentzek, A. Fuchs, W. Maier, M. Scherer, S.G. Riedel-Heller, F. Jessen and for the AgeCoDe Study Group, Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline (3) 1135–1146
- Wolk, D., see Gertje, E.C. (3) 1027–1037
- Wolk, D.A., see Lozano, A.M. (2) 777–787
- Wolk, D.A., see Roalf, D.R. (1) 325–335
- Wong, A., see Lou, W. (1) 397–409
- Wong, S., see Bertoux, M. (3) 1005–1014
- Wong, T.Y., see Liu, S. (2) 585–595
- Woodward, M., see Connors, M.H. (1) 149–155
- Wu, X., see Wang, P. (1) 359–371
- Wu, Y., see Li, Y. (1) 135–148

- Xia, W., see Sun, J. (1) 175–184
 Xiao, Z., see Yu, L. (1) 297–306
 Xie, C., see Yuan, B. (4) 1409–1423
 Xu, X., see Qiu, T. (4) 1483–1493
- Yadav, M., see Johnson, L.A. (1) 201–206
 Yakupov, E.Z., see Mukhamedyarov, M.A. (4) 1373–1383
 Yamazaki, K., see Yoshino, Y. (4) 1349–1357
 Yañez, M.J., see Estrada, L.D. (3) 1193–1205
 Yang, Y.-H., see Ho, B.-L. (1) 351–357
 Yao, L., see Wang, P. (1) 359–371
 Yasha, T.C., see Wijesinghe, P. (4) 1607–1618
 Ye, B.S., see Noh, Y. (3) 1015–1026
 Ye, Q., see Wang, P. (1) 359–371
 Yemul, S., see Varghese, M. (2) 477–496
 Yeon, B.K., see Kang, J.M. (3) 879–889
 Yoon, C.W., see Noh, Y. (3) 1015–1026
 Yoshida, T., see Yoshino, Y. (4) 1349–1357
 Yoshino, Y., T. Mori, T. Yoshida, K. Yamazaki, Y. Ozaki, T. Sao, Y. Funahashi, J.-i. Iga and S.-i. Ueno, Elevated mRNA Expression and Low Methylation of SNCA in Japanese Alzheimer's Disease Subjects (4) 1349–1357
 Young, J., see Jaakkimainen, R.L. (1) 337–349
 Yu, H., see Yu, Q. (2) 679–690
 Yu, J., see Taheri, S. (3) 1061–1072
 Yu, L., Y. Chen, W. Wang, Z. Xiao and Y. Hong, Multi-Vitamin B Supplementation Reverses Hypoxia-Induced Tau Hyperphosphorylation and Improves Memory Function in Adult Mice (1) 297–306
 Yu, Q., D. Fang, R.H. Swerdlow, H. Yu, J.X. Chen and S. ShiDu Yan, Antioxidants Rescue Mitochondrial Transport in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells (2) 679–690
 Yuan, B., C. Xie, H. Shu, W. Liao, Z. Wang, D. Liu and Z. Zhang, Differential Effects of APOE Genotypes on the Anterior and Posterior Subnetworks of Default Mode Network in Amnesic Mild Cognitive Impairment (4) 1409–1423
 Yushkevich, P., see Gertje, E.C. (3) 1027–1037
 Zafar, S., see Karch, A. (4) 1385–1393
 Zafiu, C., see Hülsemann, M. (1) 79–88
 Zago, W., see Blockx, I. (2) 723–735
 Zakarias, J.K., C. Jensen-Dahm, A. Nørgaard, L. Stevnsborg, C. Gasse, B.G. Andersen, S. Jakobsen, F.B. Waldorff, T. Moos and G. Waldemar, Geographical Variation in Antipsychotic Drug Use in Elderly Patients with Dementia: A Nationwide Study (3) 1183–1192
 Zanolungo, S., see Estrada, L.D. (3) 1193–1205
 Zefirov, A.L., see Mukhamedyarov, M.A. (4) 1373–1383
 Zerr, I., see Karch, A. (4) 1385–1393
 Zetterberg, H., see Portelius, E. (4) 1593–1605
 Zetterberg, H., see Racine, A.M. (4) 1395–1408
 Zetterberg, H., see Westona, P.S.J. (4) 1297–1302
 Zhang, H., X. Chen, F. Shi, G. Li, M. Kim, P. Giannakopoulos, S. Haller and D. Shen, Topographical Information-Based High-Order Functional Connectivity and Its Application in Abnormality Detection for Mild Cognitive Impairment (3) 1095–1112
 Zhang, J., see Wang, P. (1) 359–371
 Zhang, M., see Qiu, T. (4) 1483–1493
 Zhang, Y.-X., see Li, D. (1) 89–98
 Zhang, Z., see Chen, G. (3) 983–993
 Zhang, Z., see Yuan, B. (4) 1409–1423
 Zhou, J., see Liu, S. (2) 585–595
 Zhou, J., see Qiu, T. (4) 1483–1493
 Zhou, W., see Li, Y. (1) 135–148
 Zhou, W.-X., see Li, D. (1) 89–98
 Zhou, X., see Beckelman, B.C. (2) 669–678
 Zhu, H., see Taheri, S. (3) 1061–1072
 Zilka, N., see Zimova, I. (2) 831–843
 Zimova, I., V. Brezovakova, T. Hromadka, P. Weisova, V. Cubinkova, B. Valachova, P. Filipcik, S. Jadhav, T. Smolek, M. Novak and N. Zilka, Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy (2) 831–843